We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-5.17%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$6.16B
AUM Growth
-$821M
(-12%)
Cap. Flow
-$392M
Cap. Flow
% of AUM
-6.36%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
911
New
217
Increased
113
Reduced
100
Closed
202
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$100M |
| 2 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
+$97M |
| 3 |
Lam Research
LRCX
|
+$85.4M |
| 4 |
Boston Scientific
BSX
|
+$79.4M |
| 5 |
Merck
MRK
|
+$67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$145M |
| 2 |
ASML
ASML
|
+$119M |
| 3 |
Qorvo
QRVO
|
+$89M |
| 4 |
Microsoft
MSFT
|
+$82.9M |
| 5 |
Intuitive Surgical
ISRG
|
+$75.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.56% |
| 2 | Technology | 29.01% |
| 3 | Industrials | 8.79% |
| 4 | Communication Services | 5.99% |
| 5 | Financials | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Theravance Biopharma
TBPH
$874M
| $12.7M | 0.21% |
1,326,653
+751,540
| +131% | +$7.36M |
|
|
CERE
152
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $12.7M | 0.21% |
361,753
+124,427
| +52% | +$3.63M |
|
|
DICE
153
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $12.4M | 0.2% |
649,153
+399,104
| +160% | +$7.12M |
|
154
CRISPR Therapeutics
CRSP
$4.88B
| $11.9M | 0.19% |
189,126
+179,759
| +1,919% | +$11.3M |
|
155
MongoDB
MDB
$30.6B
| $11.9M | 0.19% |
+26,719
| New | +$10.4M |
|
156
Nerdy
NRDY
$108M
| $11.7M | 0.19% |
2,297,088
+760,917
| +50% | +$3.39M |
|
157
Vontier
VNT
$4.62B
| $11.6M | 0.19% |
+458,268
| New | +$12.1M |
|
|
ECOL
158
DELISTED
US Ecology, Inc.
ECOL
| $11.6M | 0.19% |
+241,802
| New | +$9.66M |
|
159
RadNet
RDNT
$5.25B
| $11.5M | 0.19% |
512,256
+303,194
| +145% | +$7.42M |
|
160
Biogen
BIIB
$29.8B
| $11.4M | 0.18% |
54,067
+16,286
| +43% | +$3.54M |
|
161
Pulmonx
LUNG
$89.5M
| $11.3M | 0.18% |
456,655
+95,048
| +26% | +$2.45M |
|
162
Under Armour
UAA
$2.89B
| $11.3M | 0.18% |
664,265
+495,423
| +293% | +$8.88M |
|
|
HMHC
163
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $11M | 0.18% |
+525,169
| New | +$9.9M |
|
|
VMW
164
DELISTED
VMware, Inc
VMW
| $11M | 0.18% |
+96,799
| New | +$11.7M |
|
|
KRTX
165
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $10.9M | 0.18% |
85,990
+69,226
| +413% | +$7.79M |
|
166
Estee Lauder
EL
$31.5B
| $10.9M | 0.18% |
+39,943
| New | +$12M |
|
|
IGMS
167
DELISTED
IGM Biosciences
IGMS
| $10.8M | 0.18% |
403,401
| – | – |
|
168
Silicon Laboratories
SLAB
$7.19B
| $10.6M | 0.17% |
70,709
+13,663
| +24% | +$2.18M |
|
169
Tyler Technologies
TYL
$12.5B
| $10.6M | 0.17% |
+23,822
| New | +$10.7M |
|
|
MRTX
170
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.4M | 0.17% |
126,048
+1,156
| +0.9% | +$118K |
|
|
HMCO
171
DELISTED
HumanCo Acquisition Corp. Class A Common Stock
HMCO
| $10.4M | 0.17% |
1,054,421
| – | – |
|
|
ANSS
172
DELISTED
Ansys
ANSS
| $10.2M | 0.17% |
32,061
+13,915
| +77% | +$4.54M |
|
173
ICU Medical
ICUI
$4.32B
| $10.1M | 0.16% |
45,367
-68,748
| -60% | -$15.4M |
|
174
Stevanato
STVN
$5.62B
| $10.1M | 0.16% |
500,000
| – | – |
|
175
Veeva Systems
VEEV
$33.5B
| $10M | 0.16% |
+47,291
| New | +$10.3M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Woodline Partners held 911 positions worth $6.16B, down 12% from $6.98B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners withdrew a net $392M in Q1 2022, closing 202 positions and reducing 100 holdings. Its most notable exit was AbbVie, an estimated $145M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.
Against the trend, Woodline Partners opened a new position in ZYNGA INC. CL A COMMON worth $102M.
- Woodline Partners's largest Q1 2022 buy was ZYNGA INC. CL A COMMON: 11,039,458 shares worth $102M.
- Woodline Partners added most to Seagen Inc. Common Stock in Q1 2022, an estimated $100M increase.
- Woodline Partners's biggest Q1 2022 reduction was Qorvo, cutting an estimated $89M.
- Woodline Partners fully exited AbbVie in Q1 2022, selling an estimated $145M.
- Woodline Partners's ten largest holdings make up 16% of its $6.16B portfolio in Q1 2022.
- Woodline Partners opened 217 new positions and closed 202 in Q1 2022.
- Woodline Partners's portfolio value fell 12% quarter-over-quarter to $6.16B.
Based on Woodline Partners's 13F filing for Q1 2022, filed 16 May 2022.